Figure 1



Figure 1: Competitive inhibition of ^{111}In labelled 1033-trastuzumab binding to SKBR-3 cells by cold (unlabelled, without 1033-conjugate) trastuzumab.

Figure 2



Figure 2: Comparison of whole body clearance of radioactivity in rats injected with ^{111}In-1033-trastuzumab (filled triangles) or ^{111}In-1033-rituximab (filled squares) antibody conjugates expressed as percentage ± std.dev. The data are corrected for radioactivity decay and background.

Figure 3



Figure 3: Comparison of whole blood clearance of radioactivity in rats, injected with ^{111}In-1033-trastuzumab (filled triangles) or ^{111}In-1033-rituximab (filled squares) antibody conjugates, expressed as % of activity at start ± std.dev. The data are corrected for radioactivity decay.

Figure 4



Figure 4: Biodistribution of ^{111}In-1033-trastuzumab in rats, expressed as % of injected dose per gram tissue ± std.dev. The results are corrected for radiochemical decay.

Figure 5



Figure 5: Biodistribution of ^{111}In-1033-rituximab in rats, expressed as % of injected dose per gram tissue ± std.dev. The results are corrected for radiochemical decay.